Vascular Dementia Italian Sulodexide Study (VA.D.I.S.S.) Clinical and Biological Results

Parnetti, Lucilla; Mari, Daniela; Abate, G; Balestreri, R; Cucinotta, Domenico; Coppola, R.; Cherubini, Antonio; Ferrari, P; Senin, Umberto

doi:10.1016/s0049-3848(97)00122-9

Cited by 25 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intervention trials have shown that statin therapy reduces CRP levels, and CRP level may be used to identify patients most likely to benefit from therapy (58). The use of heparin‐induced extracorporeal LDL precipitation reduces circulating fibrinogen, improves cerebral blood flow (59) and has been shown even to slow the progress of vascular dementia (60,61). Reduction of PV of upto 17% by haemopharesis has been shown to improve cognitive function (59).…”

Section: Discussionmentioning

confidence: 99%

Coagulation and inflammatory markers in Alzheimer's and vascular dementia

Gupta

Watkins

Thomas

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

Alzheimer's disease is classified as a degenerative dementia while vascular dementia is known to be associated with atherothrombosis and classical vascular risk factors. However, over the last decade, there is increasing evidence of the role of haemostatic factors and inflammatory mechanisms in the pathogenesis of Alzheimer's disease. Serum markers of hypercoagulability and markers of inflammation could lead to thrombosis, accelerated atherogenesis and resulting dementia of both Alzheimer's and vascular dementia. In this case control study, we studied these serum markers of coagulation and inflammation in patients suffering from dementia.

show abstract

Section: Discussionmentioning

confidence: 99%

Coagulation and inflammatory markers in Alzheimer's and vascular dementia

Gupta

Watkins

Thomas

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…In line with our study some researchers present some evidences of clinical improvement of the cognitive state after short-term and long-term oral administration of sulodexide. Clinical improvement of memory deficit is described [186] as well as improvement of dementia symptomatology [187] [188] and mental confusion, [189]- [191] and a remarkable improvement of psycho-sensorial disturbances, sleeping disorders [192] and beneficial effects in vascular dementia [193].…”

Section: Discussionmentioning

confidence: 99%

Sulodexide and Alzheimer’s Disease: A Preliminary Prospective Study

J¹,

Pascual-Salcedo²,

Aza-Pascual-Salcedo³

2016

WJCD

View full text Add to dashboard Cite

The purpose of this prospective study is to determine the relative incidence of Alzheimer's disease in patients treated for at least three years, with sulodexide (n = 46, 76.48 ± 7.02 years old) or acenocoumarol (n = 47, 78.21 ± 6.66 years old) in order to prevent primary and secondary venous thromboembolism and atherothrombotic disease. In the sulodexide group, there was an apparent prevention of cognitive and behavioural impairment (relative incidence: 2.02) compared with acenocoumarol group (relative incidence: 4.86). The favourable results in sulodexide group may be related to their pharmacodynamic actions of inhibition of PAI-1, which may interfere with the pathogenesis of Alzheimer's disease, and to the role of glutathione and PAI-1 in the β-amyloid system in the brain.

show abstract

“…Treatment with triflusal, an antiplatelet drug, in a randomized, open-label study, led to better scores in MMSE, compared to those of patients in the control group [63]. In a double-blind, randomized trial, treatment with sulodexide (50 mg bid, for 6 months) was associated with an improvement in GBS scores, compared to those of patients in the pentoxifylline group [64]. …”

Section: Treatment Of Vadmentioning

confidence: 99%

Neuroprotection in Vascular Dementia

et al. 2006

View full text Add to dashboard Cite

Vascular dementia (VaD) is the second most common form of dementia after Alzheimer’s disease (AD), and one of the major causes of mental and physical disability in developed countries. As such, the identification and implementation of strategies which prevent the development of the condition or enable improvements in patients with VaD are healthcare objectives of the first order. VaD is now regarded as a combined group of clinical-pathological entities rather than one disease, that is, multiple pathogenic mechanisms and lesion types underlie a cognitive impairment of vascular origin. The clinical diagnosis of VaD is complex and difficult because of the heterogeneous nature of its clinical presentation and progression and the low sensitivity of existing clinical criteria. Moreover, there is growing evidence of the epidemiological significance of mixed forms of dementia, and that ischemic processes may precipitate and exacerbate cognitive impairment in AD. Numerous compounds have been proposed as potentially useful in the treatment of patients with VaD, comprising vasodilatative, antithrombotic, hemorrheological, nootropic, antiserotoninergic and, most recently, antiglutamatergic and cholinergic approaches. In spite of some initially favorable reports based on the use of memantine, donepezil and galantamine, there is as yet no conclusive evidence of a definitive treatment for VaD. Unsatisfactory results from VaD drug trials may be attributed in part to the diversity of the patients included (underlying pathogenic mechanisms, number, type, and location of vascular lesions), and to methodological limitations in the design of the trials (outcome measures, end-points, size, follow-up period). The treatment of modifiable vascular risk factors – hypertension, diabetes mellitus, hypercholesterolemia and heart disease – is an important strategy for the reduction of the risk of dementia, and is likely to slow the progress of cognitive decline.

show abstract

Vascular Dementia Italian Sulodexide Study (VA.D.I.S.S.) Clinical and Biological Results

Cited by 25 publications

References 28 publications

Coagulation and inflammatory markers in Alzheimer's and vascular dementia

Coagulation and inflammatory markers in Alzheimer's and vascular dementia

Sulodexide and Alzheimer’s Disease: A Preliminary Prospective Study

Neuroprotection in Vascular Dementia

Contact Info

Product

Resources

About